Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)

    Funds for research to enhance recognition and eliminate HIV-1 infected cells by targeting cell surface HIV envelope for immunotherapies and vaccines.

    OverviewSimilar Grants
    OverviewSimilar Grants

    This grant is no longer accepting proposals

    National Institutes of Health has archived this opportunity.

    Funder: National Institutes of Health

    Due Dates: May 7, 2025 | September 7, 2025 | January 7, 2026 | February 19, 2026 (final closing date)

    Funding Amounts: No budget limit; maximum project period is 5 years; budgets must reflect actual project needs.

    Summary: Supports research on HIV-1 Envelope (Env) cell surface expression, mechanisms of cell elimination, and novel strategies to enhance immune recognition and elimination of HIV-1-infected cells.

    Key Information: Clinical trials are not allowed; final application deadline is February 19, 2026 due to early NOFO expiration.


    Description

    This opportunity from the National Institutes of Health (NIH), administered by the National Institute of Allergy and Infectious Diseases (NIAID), is designed to support research projects focused on understanding and targeting the HIV-1 Envelope (Env) protein expressed on the surface of infected cells. The program aims to advance knowledge of Env biology, elucidate the structural mechanisms of biologic-mediated cell killing, and develop innovative strategies to enhance the immune system’s ability to recognize and eliminate Env-expressing, HIV-1-infected cells. Outcomes are expected to inform the development of next-generation immunotherapies and vaccines for HIV-1 prevention and cure.

    Projects may include basic research on Env expression and trafficking, studies of host-pathogen interactions impacting Env surface levels, and translational work developing or optimizing engineered antibodies, T/NK cell engagers, or CAR T/NK cells. Applications solely focused on transcriptional control of Env, discovery of new latency reversal agents, or high-throughput screening of small molecule inhibitors are not responsive to this NOFO.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.